Investors Sell Johnson & Johnson (JNJ) on Strength on Insider Selling

Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Friday following insider selling activity. $111.50 million flowed into the stock on the tick-up and $145.73 million flowed out of the stock on the tick-down, for a money net flow of $34.23 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 19th highest net out-flow for the day. Johnson & Johnson traded up $0.04 for the day and closed at $145.34Specifically, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Joaquin Duato sold 40,000 shares of the stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $144.36, for a total value of $5,774,400.00. Following the sale, the insider now directly owns 112,848 shares in the company, valued at $16,290,737.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 85,340 shares of company stock worth $11,992,396. 0.22% of the stock is currently owned by insiders.

Several analysts have recently issued reports on the company. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 target price on shares of Johnson & Johnson in a report on Friday, September 14th. Jefferies Financial Group set a $145.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Sunday, July 15th. HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, October 14th. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and a consensus price target of $142.54.

The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. The stock has a market capitalization of $382.50 billion, a price-to-earnings ratio of 19.91, a price-to-earnings-growth ratio of 2.23 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The business had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. During the same period in the prior year, the company earned $1.90 EPS. Johnson & Johnson’s revenue for the quarter was up 3.6% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 8.16 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be given a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a dividend yield of 2.48%. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

Institutional investors have recently bought and sold shares of the business. Selective Wealth Management bought a new position in Johnson & Johnson in the third quarter valued at about $105,000. Financial Gravity Wealth Inc. bought a new position in shares of Johnson & Johnson during the first quarter worth about $105,000. CSat Investment Advisory L.P. bought a new position in shares of Johnson & Johnson during the second quarter worth about $107,000. WP Advisors LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $108,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $117,000. Hedge funds and other institutional investors own 66.60% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.wkrb13.com/2018/11/10/investors-sell-johnson-johnson-jnj-on-strength-on-insider-selling.html.

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: How does inflation affect different investments?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply